Bibliography

NDA 20-386

COZAAR

Advisory Committee

April 12, 2002

Agodoa, L.Y., Appel, L., et al. Effect of ramipril vs amlodipine on
renal outcomes in hypertensive nephrosclerosis. JAMA 1996;
285:2719-2727.

Brenner, B.M., Cooper, M.E., et al. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. The New England Journal of Medicine 2001; 345:861-869.

Cordonnier, D J., Pinel, N., et al. Expansion of cortical interstitium
is limited by converting enzyme inhibition in type 2 diabetic patients
with glomerulosclerosis. Journal of the American Society of Nephrology
1999; 10:1253-1263.

The EUCLID Study Group. Randomised placebo-controlled trial of
lisinopril in normotensive patients with insulin-dependent diabetes and
normoalbuminuria or microalbuminuria. The Lancet 1997; 349:1787-1792.

The GISEN Group. Randomised placebo-controlled trial of effect of
ramipril on decline in glomerular filtration rate and risk of terminal
renal failure in proteinuric, non-diabetic nephropathy. The Lancet 1997;
349:1857-1863.

Ihle, B.U., Whitworth, J.A., et al. Angiotensin-converting enzyme
inhibition in nondiabetic progressive renal insufficiency: A controlled
double-blind trial. American Journal of Kidney Diseases 1996;
27:489-495.

Laffel, L., McGill, J., Gans, D.J. The beneficial effect of
angiotensin-converting enzyme inhibition with captopril on diabetic
nephropathy in normotensive IDDM patients with microalbuminuria. The
American Journal of Medicine 1995; 99:497-504.

Lebovitz, H.E., Wiegmann, T.B., et al. Renal protective effects of
enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney
International 1994; 45:S-150-S-155.

Lewis, E.J., Hunsicker, L.G., Bain, R.P., Rohde, R.D. The effect of
angiotensin-converting-enzyme inhibition on diabetic nephropathy. The
New England Journal of Medicine 1993;329:1456-1497.

Lewis, E.J., Hunsicker, L.G., et al. Renoprotective effect of the
angiotensin receptor antagonist irbesartan in patients with nephropathy
due to type 2 diabetes. The New England Journal of Medicine 2001;
345:851-860.

Maschio, G., Alberti, D., et al. Effect of the
angiotensin-converting-enzyme inhibitor benazepril on the progression of
chronic renal insufficiency. The New England Journal of Medicine 1996;
334:939-945.

Parving, H., Lehnert, H., et al. The effect of irbesartan on the
development of diabetic nephropathy in patients with type 2 diabetes.
The New England Journal of Medicine 2001; 345:870-878.

Ravid, M., Lang, R., Rachmani, R, Lishner, M. Long-term renoprotective
effect of angiotensin-converting enzyme inhibition in
non-insulin-dependent diabetes mellitus.

Arch Intern Med 1996; 156:286-289.

Remuzzi, G., Ruggenenti, P. Slowing the progression of diabetic
nephropaty. The New England Journal of Medicine 1993;329:1496-1497.

Ruggenenti, P., Perna, A., et al. Renal function and requirement for
dialysis in chronic nephropathy patients on long-term ramipril: REIN
follow-up trial. The Lancet

1998; 352:1252-1256.

Ruggenenti, P., Perna, A., et al. Renoprotective properties of
ACE-inhibition in non-diabetic nephropathies with non-nephrotic
proteinuria. The Lancet 1999; 354:359-364.